Rising number of molecules gaining BT status along with increasing number of cancer patients requiring therapies and drugs used to treat rare disease is predicted to boost the global breakthrough therapies industry size over the forecast period. Upsurge in prevalence of cancer and high spending in healthcare will further accelerate the business growth.
Developed region with better reimbursement policies and infrastructure will favour the industry growth over the coming years. As per European Federation of Pharmaceutical Industries and Associations, diseases relevant to nervous system, digestive system, respiratory system, cancer, and cardiovascular system are the major reasons for death in Europe.
The breakthrough therapies market is segmented on the lines of its application and regional. The basis of application the market is segmented into Oncology, Infectious Diseases, Rare Diseases, Autoimmune Diseases, Pulmonary Diseases, and Neurological Disorders. The breakthrough therapies market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, and Rest of World. Each geographic market is further segmented to provide market revenue for selected countries such as the U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Roche, Novartis International AG, Regeneron, Acadia, Boehringer Ingelheim, GlaxoSmithKline, Vertex, Alexion, Merck, and Takeda are among the major players in the global breakthrough therapies market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Breakthrough Therapies Market has been segmented as below:
Breakthrough Therapies Market, By Application
Breakthrough Therapies Market, By Region
The report covers:
Report scope:
The scope of the report includes a detailed study of breakthrough therapies market with the reasons given for variations in the growth of the industry in certain regions.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Roche, Novartis International AG, Regeneron, Acadia, Boehringer Ingelheim, GlaxoSmithKline, Vertex, Alexion, Merck, and Takeda. Company profile includes assigning such as company overview, product landscape, financial overview, and recent developments.
The top company reports are intended to provide our buyers with a snapshot of the industry’s most influential players.
Reasons to Buy this Report:
Customization:
We can offer you custom research reports as per client’s special requirements
Below are our new reports:
Global Veterinary Blood Pressure Monitors Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising number of drugs gaining BT status
4.2.2. Expedited approval process adopted in Europe
4.3. Restraints
4.3.1. High price of BT drugs
4.4. Opportunities
4.4.1. Growth in developed regions owing to better reimbursement policies
4.5. Challenges
4.5.1. Shifting preference for generics
5. Breakthrough Therapies Market, By Application
5.1. Key Points
5.2. Oncology
5.3. Infectious Diseases
5.4. Rare Diseases
5.5. Autoimmune Diseases
5.6. Pulmonary Diseases
5.7. Neurological Disorders
6. Competitive Landscape
6.1. Introduction
6.2. Recent Developments
6.2.1. Mergers & Acquisitions
6.2.2. New Product Developments
6.2.3. Portfolio/Production Capacity Expansions
6.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
6.2.5. Others
7. Company Profile
7.1. Roche
7.1.1. Company Overview
7.1.2. Product/Service Landscape
7.1.3. Financial Overview
7.1.4. Recent Developments
7.2. Novartis International AG
7.2.1. Company Overview
7.2.2. Product/Service Landscape
7.2.3. Financial Overview
7.2.4. Recent Developments
7.3. Regeneron
7.3.1. Company Overview
7.3.2. Product/Service Landscape
7.3.3. Financial Overview
7.3.4. Recent Developments
7.4. Acadia
7.4.1. Company Overview
7.4.2. Product/Service Landscape
7.4.3. Financial Overview
7.4.4. Recent Developments
7.5. Boehringer Ingelheim
7.5.1. Company Overview
7.5.2. Product/Service Landscape
7.5.3. Financial Overview
7.5.4. Recent Developments
7.6. GlaxoSmithKline
7.6.1. Company Overview
7.6.2. Product/Service Landscape
7.6.3. Financial Overview
7.6.4. Recent Developments
7.7. Vertex
7.7.1. Company Overview
7.7.2. Product/Service Landscape
7.7.3. Financial Overview
7.7.4. Recent Developments
7.8. Alexion
7.8.1. Company Overview
7.8.2. Product/Service Landscape
7.8.3. Financial Overview
7.8.4. Recent Developments
7.9. Merck
7.9.1. Company Overview
7.9.2. Product/Service Landscape
7.9.3. Financial Overview
7.9.4. Recent Developments
7.10. Takeda
7.10.1. Company Overview
7.10.2. Product/Service Landscape
7.10.3. Financial Overview
7.10.4. Recent Developments
7.11. Pfizer
7.11.1. Company Overview
7.11.2. Product/Service Landscape
7.11.3. Financial Overview
7.11.4. Recent Developments
The Breakthrough Therapies Market has been segmented as below:
Breakthrough Therapies Market, By Application
Breakthrough Therapies Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
